brentuximab vedotin
takeda,seagen
['brentuximab vedotin', 'great work']
excited to have been a part of this great work by real world outcomes for brentuximab vedotin for maintenance after auto sct in high risk chl. only 51-75% of the total bv dose may provide similar pfs benefit. #asco22 
Born in Bosnia-Herzegovina, grew up in Boston, now Hematologist in Oklahoma City @OUMedicine@StephensonCC